Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific ConferenceGlobeNewsWire • 03/09/26
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALSGlobeNewsWire • 03/09/26
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/04/26
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/04/26
Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewsWire • 02/18/26
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?Zacks Investment Research • 02/18/26
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?Zacks Investment Research • 01/16/26
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?Zacks Investment Research • 01/15/26
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom FisherZacks Investment Research • 12/22/25
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026Zacks Investment Research • 12/16/25
Buy These 5 Best Value Stocks to Boost Your Portfolio in DecemberZacks Investment Research • 12/15/25
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 12/12/25